Research Topics
| R B AylwardSummaryAffiliation: World Health Organization Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
The global polio eradication initiative: lessons learned and prospects for successBruce Aylward
World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland
Vaccine 29:D80-5. 2011....
Risk management in a polio-free worldR Bruce Aylward
Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
Risk Anal 26:1441-8. 2006....
Eradicating polio: today's challenges and tomorrow's legacyR B Aylward
Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
Ann Trop Med Parasitol 100:401-13. 2006....
Interrupting poliovirus transmission -- new solutions to an old problemR Bruce Aylward
Global Polio Eradication Initiative, WHO, 20 Avenue Appia, Geneva 1211, Switzerland
Biologicals 34:133-9. 2006....
The human storyR Bruce Aylward
World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland
BMJ 331:1261-2. 2005
Policy. OPV cessation--the final step to a "polio-free" worldR Bruce Aylward
Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland
Science 310:625-6. 2005..This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines...
Polio eradication: mobilizing and managing the human resourcesR Bruce Aylward
Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
Bull World Health Organ 83:268-73. 2005....
Can we capitalize on the virtues of vaccines? Insights from the polio eradication initiativeR Bruce Aylward
Polio Eradication Initiative, World Health Organization, 20, Avenue Appia, CH 1211 Geneva 27, Switzerland
Am J Public Health 95:773-7. 2005....
Disease eradication as a public health strategy: a case study of poliomyelitis eradicationR B Aylward
Expanded Programme on Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
Bull World Health Organ 78:285-97. 2000..When the humanitarian, economic and consequent benefits of this initiative are measured against the costs, a strong argument is made for eradication as a valuable disease control strategy...
Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmissionR Bruce Aylward
World Health Organization, Geneva, Switzerland
Bull World Health Organ 82:40-6. 2004..However, this framework must be regarded as a dynamic tool, requiring regular updating as additional information on these risks becomes available through further scientific research, programmatic work, and policy decisions...
Global health goals: lessons from the worldwide effort to eradicate poliomyelitisR Bruce Aylward
Global Polio Eradication Initiative, Department of Vaccines and Biologicals, Geneva, Switzerland
Lancet 362:909-14. 2003..The greatest threats to poliomyelitis eradication are a financing gap of US 210 million dollars and difficulties in strategy implementation in at most five countries...
A global call for new polio vaccinesDavid L Heymann
Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, CH-1211 Geneva, Switzerland
Nature 434:699-700. 2005
Eradicating polioDavid L Heymann
Polio Eradication Initiative, World Health Organization, Geneva
N Engl J Med 351:1275-7. 2004
Perspectives from the global poliomyelitis eradication initiativeH F Hull
World Health Organization, Geneva, Switzerland
Bull World Health Organ 76:42-6. 1998..Careful consideration should be given in the planning phases of a disease control initiative on how the initiative can be used to support other health initiatives...
Eradication of poliomyelitis in countries affected by conflictR H Tangermann
World Health Organization, Geneva, Switzerland
Bull World Health Organ 78:330-8. 2000..The goal of polio eradication by the end of 2000 remains attainable if supplementary immunization and surveillance can be accelerated in countries affected by conflict...
Progress towards global polio eradicationH F Hull
Department of Vaccines and Biologicals, World Health Organization, 1211, Geneva, Switzerland
Vaccine 19:4378-84. 2001..With global eradication imminent, WHO is preparing for post-eradication issues: containment of polioviruses, certification of eradication, and stopping immunization...
A vision of a world without polio: the OPV cessation strategyDavid L Heymann
World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
Biologicals 34:75-9. 2006..Final preparations for the eventual global and simultaneous cessation of OPV will require the same level of international cooperation and coordination that has brought the world to the verge of polio eradication...
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trialRoland W Sutter
World Health Organization, Geneva, Switzerland
Lancet 376:1682-8. 2010..Poliovirus types 1 and 3 co-circulate in poliomyelitis-endemic countries. We aimed to assess the immunogenicity of a novel bivalent types 1 and 3 oral poliovirus vaccine (bOPV)...
Poliomyelitis eradication and pandemic influenzaDavid L Heymann
Polio Eradication Initiative, World Health Organization, Geneva 27, Switzerland
Lancet 367:1462-4. 2006
Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free worldDavid L Heymann
Polio Eradication InitiativeWHO, Geneva 1211, Switzerland
Lancet 363:1566-8. 2004
Mass vaccination: when and whyD L Heymann
World Health Organization, Geneva, Switzerland
Curr Top Microbiol Immunol 304:1-16. 2006..In the twenty-first century, mass vaccination and routine immunization remain a necessary alliance for attaining both national and international goals in the control of vaccine preventable disease...
New strategies for the elimination of polio from IndiaNicholas C Grassly
Department of Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, UK
Science 314:1150-3. 2006..We analyze strategies to counteract this and show that switching to monovalent vaccine may finally interrupt virus transmission...
Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modelingKimberly M Thompson
Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, 3rd Floor, Boston, MA 02115, USA
Risk Anal 26:1571-80. 2006..This analytical journey has provided several key insights and lessons learned that will be useful to future analysts involved in similar complex decision-making processes...
Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control studyNicholas C Grassly
Department of Infectious Disease Epidemiology, Imperial College London, London, UK
Lancet 369:1356-62. 2007..A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected countries. Our aim was to assess the efficacy of this vaccine in India...
The risks, costs, and benefits of possible future global policies for managing poliovirusesKimberly M Thompson
Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, Third Floor, Boston, MA 02115, USA
Am J Public Health 98:1322-30. 2008..We assessed the costs, risks, and benefits of possible future major policy decisions on vaccination, surveillance, response plans, and containment following global eradication of wild polioviruses...
Effectiveness of immunization against paralytic poliomyelitis in NigeriaHelen E Jenkins
Medical Research Council Centre for Outbreak Analysis and Modeling, Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, United Kingdom
N Engl J Med 359:1666-74. 2008..Understanding the relative contribution of these vaccines and the improved coverage to the decline in incident cases is essential for future planning...
The polio eradication endgame. As polio eradication nears realization, such real-world vaccination strategies could hold lessons for the future in AIDS vaccine developmentDavid L Heymann
IAVI Rep 10:13-7. 2006
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradicationRadboud J Duintjer Tebbens
Kids Risk Project, Harvard School of Public Health, Boston, MA, USA
Risk Anal 26:1471-505. 2006..This article attempts to comprehensively characterize the risks, synthesize the existing data available for modeling them, and present quantitative risk estimates that can provide a starting point for informing policy decisions...
